
PetMed Express PETS
$ 3.01
0.88%
Annual report 2025
added 10-14-2025
PetMed Express Accounts Receivables 2011-2025 | PETS
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables PetMed Express
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.32 M | 3.28 M | 1.74 M | 1.91 M | 2.59 M | 3.84 M | 2.54 M | 2.29 M | 1.81 M | 1.72 M | 1.93 M | 1.76 M | 1.44 M | 1.57 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.84 M | 1.44 M | 2.2 M |
Quarterly Accounts Receivables PetMed Express
| 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.26 M | 1.62 M | 2.26 M | 3.28 M | 1.93 M | 2.17 M | - | 1.74 M | 1.94 M | 1.59 M | - | 1.91 M | 1.27 M | 1.85 M | 2.16 M | 2.59 M | 1.83 M | 2.21 M | 2.71 M | 3.84 M | 2.05 M | 1.47 M | 2.14 M | 2.54 M | 1.27 M | 1.79 M | 2.43 M | 2.29 M | 1.72 M | 2.01 M | 2.06 M | 1.81 M | 1.54 M | 1.37 M | 2.08 M | 1.72 M | 1.36 M | 1.62 M | 3.09 M | 1.93 M | 1.35 M | 1.96 M | 1.6 M | 1.76 M | 1.65 M | 1.38 M | 2.53 M | 1.44 M | 744 K | 1.89 M | 2.39 M | 1.57 M | 1.64 M | 1.43 M | 2.3 M | 1.98 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.84 M | 744 K | 1.95 M |
Accounts Receivables of other stocks in the Pharmaceutical retailers industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Greenlane Holdings
GNLN
|
6.47 M | $ 3.09 | 3.17 % | $ 23.3 M | ||
|
Trxade Group
MEDS
|
822 K | - | 4.55 % | $ 5.8 M | ||
|
BOQI International Medical
BIMI
|
3.21 M | - | 6.33 % | $ 5.86 M | ||
|
LifeMD
LFMD
|
5.28 M | $ 3.43 | -1.01 % | $ 116 M | ||
|
Rite Aid Corporation
RAD
|
1.15 B | - | - | $ 35.5 M | ||
|
111
YI
|
163 M | $ 3.6 | -3.74 % | $ 619 M | ||
|
Walgreens Boots Alliance
WBA
|
5.85 B | - | - | $ 10.3 B |